Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089400 | 0.79 | ANPEP (0.41) | MAPTHTTANPEPNPC1RAB9A | |
| SCHEMBL27900467 | 0.78 | MAPT (0.50) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL27988467 | 0.74 | MAPT (0.47) | MAPTHTTP2RX7NPC1RAB9A | |
| SCHEMBL2255462 | 0.74 | ALDH1A1 (0.50) | MAPTNPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL11405226 | 0.73 | MAPT (0.48) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL8984386 | 0.72 | MAPT (0.52) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL29617680 | 0.72 | MAPT (0.52) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL28235239 | 0.72 | HTT (0.44) | MAPTHTTP2RX7NPC1RAB9A | |
| SCHEMBL29607224 | 0.72 | ALDH1A1 (0.51) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL20960317 | 0.72 | ALDH1A1 (0.46) | NPC1RAB9AHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268675-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-111788185-B | Diaryl substituted 6,5 fused ring compounds as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-3728203-B1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230115912-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-110997674-B | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| EP-3630775-B1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11478460-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-111788185-A | Diaryl substituted 6,5 fused ring compounds as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-110997674-A | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268675-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | MAPT 4600/4885HTT 3894/4885P2RX7 124/4885 |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | MAPT 4546/4885HTT 4211/4885P2RX7 206/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | MAPT 4546/4885HTT 4211/4885P2RX7 206/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | MAPT 4546/4885HTT 4211/4885P2RX7 206/4885 |
| US-20230115912-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | MAPT 4600/4885HTT 3894/4885P2RX7 124/4885 |
| US-11478460-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | MAPT 4600/4885HTT 3894/4885P2RX7 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.